The return on investment in health care: From 1980 to 2000

Value in Health

Volumn 9, Issue 3, 2006, Pages 146-156

  Luce, Bryan R ^a   Mauskopf, Josephine ^b   Sloan, Frank A ^c   Ostermann, Jan ^c   Paramore, L Clark ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b RTI INTERNATIONAL   (United States)

^c DUKE UNIVERSITY   (United States)

Author keywords

Health policy; Innovation; Medicare claims; Return on investment

Indexed keywords

ARTICLE; BREAST CANCER; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH STATUS; HEART INFARCTION; INVESTMENT; MEDICARE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; STROKE; UNITED STATES;

EID: 33646228648     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2006.00095.x     Document Type: Article

References (47)

1. Centers for Medicare and Medicaid Services, Office of the Actuary, National Health Statistics Group. 2002 National Health Care Expenditures Data Files for Downloading, File nhegdp02zip Available from: [Accessed September 8, 2004].
2. Associated Press. Kerry chides Bush on Medicare Washington Post September 7, 2004 Page A8.
3. Nordhaus W The Health of Nations: The Contribution of Improved Health to Living Standards NBER Working Paper Series 8818. Cambridge, MA National Bureau of Economic Research 2002
4. Murphy K Topel R The Economic Value of Medical Research 1999 Available from: [Last accessed June 19, 2005].
5. Lichtenberg FR Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS Health Aff 2001 20 241 51
6. Cutler DM McClellan M Is technological change in medicine worth it? Health Aff 2001 20 11 29
7. Thorpe KE Florence CS Joski P Which medical conditions account for the rise in health care spending? Health Aff 2004 10.1377hlthaff.w4.437. Available from: )/hlthaff.w4.437 [Last accessed December 19, 2005].
8. Bureau of Labor Statistics. U.S. Department of Labor. Consumer Price Index Available from: [Accessed August 24, 2004; last accessed December 19, 2005].
9. Cutler DM Kadiyala S The Economics of Better Health: The Case of Cardiovascular Disease Cambridge Harvard University 1999
10. Sloan FA Ostermann J Brown DS The rising cost of Medicare and improvements in survival and functioning among the U.S. elderly 1985-2000 In Cutler DM Garber A eds Frontiers in Health Policy Research Vol. 8 Cambridge, MA MIT Press 2005
11. Perreira KM Sloan FA Living healthy and living long: valuing the nonpecuniary loss from disability and death J Risk Uncertain 2002 24 5 29
12. U.S. Census Bureau. Statistical Abstract of the United States 2000 Available from: [Last accessed May 7, 2003].
13. Rhoades JA Sommers JP Nursing Home Expenses, 1987 and 1996 Rockville, MD Agency for Healthcare Research and Quality 2001 MEPS Chartbook No. 6. AHRQ Publications, No. 01-0029.
14. Viscusi WK The value of risks to life and health J Econ Lit 1993 31 1912 46
15. Cutler D Richardson E Measuring the Health of the USPopulationBrookings Papers on Economic Activity: Microeconomics Washington, DC The Brookings Institution 1997
16. Mrozek JR Taylor LO What determines the value of life? A meta-analysis J Policy Anal Manage 2003 253 70
17. Health United States. Centers for Disease ControlNational Center for Health Statistics 2002 Available from: [Accessed August 15, 2003].
18. Grover SA Coupal L Zowall H et al. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease Diabetes Care 2001 24 45 50
19. World Bank. World Development ReportInvesting in Health Washington, DC World Bank 2002
20. Gerdtham U-G Jonsson B International comparisons of health expenditure In: Culyer AJ Newhouse JP eds The Handbook of Health Economics (Vols 1A and 1B; Chapter 1). Amsterdam Elsevier Science 2000
21. Hirth RA Chernew ME Miller E et al. Willingness to pay for a quality-adjusted life year: in search of a standard Med Decis Making 2000 20 332 42
22. Cutler D Meara E Changes in the Age Distribution of Mortality Over the 20th Century Cambridge, MA National Bureau of Economic Research 2001 Working Paper No. w8556.
23. Viscusi W Kip A The Value of a Statistical Life: A Critical Review of Market Estimates throughout the World Cambridge National Bureau of Economics Research 2003 NBER Working Paper Series #9487.
24. Blomquist GC Economics of Value of LifeInternational Encyclopedia of the Social andBehavioral Sciences Amsterdam Elsevier Science 2001
25. U.S. Department of Health and Human Services. Summary Health Statistics for USAdults: National Health Interview Survey, 2002 Centers for Disease Control and Prevention. National Center for Health Statistics, DHHS Publication No. (PHS) 2004-1550.
26. Cretin S Cost/benefit analysis of treatment and prevention of myocardial infarction Health Serv Res Summer 1977 12 174 89
27. Goldman L Sia STB Cook EF et al. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction N Engl J Med 1988 319 152 7
28. Mark DB Hlatky MA Califf RM et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction N Engl J Med 1995 332 1418 24
29. Kuntz KM Tsevat J Goldman L Weinstein MC Cost-effectiveness of routine coronary angiography after acute myocardial infarction Circulation 1996 94 957 65
30. Phillips KA Shlipak MG Coxson P et al. Health and economic benefits of increased b-blocker use following myocardial infarction JAMA 2000 284 2748 54
31. Cohen DJ Taira DA Berezin R et al. Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the Stent Primary Angioplasty in Myocardial Infarction (Stent-PAMI) Trial Circulation 2001 104 3039 45
32. Tsevat J Kuntz KM Orav EJ et al. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels Am Heart J 2001 141 727 34
33. Eastman RC Javitt JC Herman WH et al. Model of complications of NIDDM. analysis of the health benefits and cost-effective-ness of treating NIDDM with the goal of normoglycemia Diabetes Care 1997 20 735 44
34. The CDC Diabetes Cost-Effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes JAMA 2002 287 2542 51
35. Elliott WJ Weir DR Black HR Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients Arch Intern Med 2000 160 1277 83
36. Golan L Birkmeyer JD Welch G The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors Ann Intern Med 1999 131 660 7
37. Javitt JC Aiello LP Cost-effectiveness of detecting and treating diabetic retinopathy Ann Intern Med 1996 124 1 Pt 2 164 9
38. Nussbaum ES Heros RC Erickson DL Cost-effectiveness of carotid endarterectomy Neurosurgery 1996 38 237 44
39. Sarasin FP Gaspoz JM Bounameaux H Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack Arch Intern Med 2000 160 2773 8
40. Fagan SC Morgenstern LB Petitta A et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke Neurology 1998 50 883 90
41. Desch CE Hillner BE Smith TJ Retchin SM Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes J Clin Oncol 1993 11 777 82
42. Hayman JA Hillner BE Harris JR Weeks JC Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer J Clin Oncol 1998 16 1022 9
43. Hillner BE Smith TJ Estimating the efficacy and cost-effectiveness of tamoxifen (TAM) versus TAM plus adjuvant chemotherapy in post-menopausal node-positive breast cancer. A decision analysis model Proc Am Soc Clin Oncol 1992 11 A55
44. Hillner BE Smith TJ Desch CE Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results JAMA 1992 267 2055 61
45. Karnon J Jones T A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy Pharmacoeconomics 2003 21 513 25
46. Lindfors KK Rosenquist CJ Needle core biopsy guided with mammography: a study of cost-effectiveness Radiology 1994 190 217 22
47. Smith TJ Hillner BE The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women J Clin Oncol 1993 16 1 10